2023 European Society for Medical Oncology (ESMO) Congress
Bibliographic record
Abstract
The European Society for Medical Oncology (ESMO) Congress, held in Madrid, Spain and online on October 20-24, 2023, provided a comprehensive update on the latest breakthroughs in cancer research.The program focused on recent advances in basic science, translational research, and clinical study results, as well as prevention, screening, and early diagnosis, and aimed to help participants understand and optimize the clinical implementation of these advancements.This year's congress included over 2500 abstracts, with more than 33 000 participants from 155 countries.Following the congress on November 1, the Canadian Urological Association (CUA) held an online webinar, where Canadian experts reviewed the latest evidence in urologic cancers.This report highlights the most relevant and cutting-edge advances in prostate, kidney, and bladder cancers.The entire webinar can be viewed on UROpedia Canada, and meeting abstracts can be found on ESMO oncologyPRO. PROSTATE CANCERDr. Kim Chi presented novel and potentially impactful findings in prostate cancer.The final analysis of the MAGNITUDE trial, a phase 3, randomized, doubleblind, placebo-controlled study, evaluated the combination of niraparib (NIRA), a poly(ADP-ribose) polymerase inhibitor (PARPi), with abiraterone acetate plus prednisone (AAP) as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.1 mCRPC patients with HRR gene alterations, BRCA1 and BRCA2 in particular, have poor outcomes compared to patients without these gene alterations.At primary analysis, MAGNITUDE demonstrated significant improvement in radiographic progressionfree survival (rPFS) with NIRA + AAP compared with placebo + AAP in patients with BRCA-mutated mCRPC (hazard ratio [HR] 0.53, p=0.001).The final, pre-planned, event-driven overall survival (OS) analysis was conducted after a median followup of 35.9 months, with a focus on patients with BRCA-mutated mCRPC.The median treatment duration was 20.5 months for the NIRA + AAP arm and 14.4 months for the placebo + AAP arm.Final OS analysis demonstrated no significant difference, with a median survival of 30 months for those on NIRA compared to 28.6 months for those on placebo (HR 0.788).A pre-planned multivariate analysis adjusting for baseline imbalances demonstrated an OS benefit favoring NIRA + AAP (HR 0.663, p=0.0237), this despite 70% of NIRA vs. 86% of placebo patients receiving subsequent life-prolonging therapy, including over 40% of placebo patients receiving a subsequent PARPi or cisplatin-based chemotherapy.Other endpoints, such as time to symptomatic progression and time to cytotoxic chemotherapy, were also in favor of NIRA.Adverse events (AEs) were as expected, with greater AEs associated with NIRA.This analysis supports the positive benefit-risk profile of first-line NIRA with AAP as a new standard of care for patients with BRCA-mutated mCRPC.This further demonstrates the benefit of earlier use of PARPi with androgen receptor pathway inhibition (ARPI) as first-line therapy for mCRPC in patients with BRCA1/2 mutations in line with the PROpel 2 and TALAPRO-2 3 studies.These studies emphasize the need for tumor and germline testing to identify HHR alterations for patients with metastatic prostate cancer.A health-related quality-of-life (QoL) analysis was performed in patients participating in the EMBARK study.4 In this study, patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.006 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.002 | 0.001 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.006 | 0.001 |
| Open science | 0.001 | 0.003 |
| Research integrity | 0.005 | 0.003 |
| Insufficient payload (model declined to judge) | 0.372 | 0.252 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".